Omnicell, Inc. (OMCL) 10-Year Financial Performance & Capital Metrics

OMCL • • Industrial / General

HealthcareHealthcare ITClinical Software & EHR SystemsElectronic Health Record Systems

AboutOmnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.Show more

Revenue $1.11B -3.0%
EBITDA $90M +18.2%
Net Income $13M +161.5%
EPS (Diluted) 0.27 +160.0%
Gross Margin 42.35% -2.8%
EBITDA Margin 8.1% +21.9%
Operating Margin 0.03% +101.8%
Net Margin 1.13% +163.4%
ROE 1.03% +158.7%
ROIC 0.02% +101.9%
Debt/Equity 0.31 -40.4%
Interest Coverage 0.07

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 90 (top 10%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Profits declining 27.2% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.69%

5Y4.39%

3Y-0.59%

TTM10.67%

Profit (Net Income) CAGR

10Y-8.52%

5Y-27.21%

3Y-45.6%

TTM212.63%

EPS CAGR

10Y-10.62%

5Y-28.35%

3Y-44.97%

TTM210.57%

ROCE

10Y Avg3.43%

5Y Avg1.59%

3Y Avg-0.4%

Latest0.02%

Peer Comparison

Electronic Health Record Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
OMCLOmnicell, Inc.	2.28B	50.72	187.85	-3.04%	1.69%	1.63%	6.65%	0.31
NUTXNutex Health, Inc.	1.17B	165.90	17.09	93.8%	11.63%	26.04%	1.78%	1.69
SYSo-Young International Inc.	226.9M	2.70	-0.62	-2.09%	-51.75%	-41.37%		0.12
CCLDCareCloud, Inc.	121.68M	2.87	-10.25	-5.32%	9.8%	19.39%	15.57%	0.07
PHRPhreesia, Inc.	971.22M	16.11	-15.79	17.83%	-1.16%	-1.68%	0.85%	0.07

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	484.56M	692.62M	716.16M	787.31M	897.03M	892.21M	1.13B	1.3B	1.15B	1.11B
Revenue Growth %	0.1%	0.43%	0.03%	0.1%	0.14%	-0.01%	0.27%	0.14%	-0.11%	-0.03%
Cost of Goods Sold+	236.63M	378.82M	394.08M	414.98M	460.12M	478.92M	577.37M	706.96M	647.18M	641.24M
COGS % of Revenue	0.49%	0.55%	0.55%	0.53%	0.51%	0.54%	0.51%	0.55%	0.56%	0.58%
Gross Profit+	247.93M	313.8M	322.09M	372.33M	436.91M	413.29M	554.65M	588.99M	499.93M	471M
Gross Margin %	0.51%	0.45%	0.45%	0.47%	0.49%	0.46%	0.49%	0.45%	0.44%	0.42%
Gross Profit Growth %	0.06%	0.27%	0.03%	0.16%	0.17%	-0.05%	0.34%	0.06%	-0.15%	-0.06%
Operating Expenses+	202.74M	307.32M	316.33M	327.94M	358.56M	377.77M	465.15M	591.31M	519.26M	470.67M
OpEx % of Revenue	0.42%	0.44%	0.44%	0.42%	0.4%	0.42%	0.41%	0.46%	0.45%	0.42%
Selling, General & Admin	167.58M	249.52M	250.31M	263.1M	289.92M	307.61M	389.43M	486.34M	425.97M	380.25M
SG&A % of Revenue	0.35%	0.36%	0.35%	0.33%	0.32%	0.34%	0.34%	0.38%	0.37%	0.34%
Research & Development	35.16M	57.8M	66.02M	64.84M	68.64M	70.16M	75.72M	104.97M	93.29M	90.41M
R&D % of Revenue	0.07%	0.08%	0.09%	0.08%	0.08%	0.08%	0.07%	0.08%	0.08%	0.08%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	48.63M	6.48M	5.75M	44.39M	78.35M	35.53M	89.51M	-2.32M	-19.33M	337K
Operating Margin %	0.1%	0.01%	0.01%	0.06%	0.09%	0.04%	0.08%	-0%	-0.02%	0%
Operating Income Growth %	-0.02%	-0.87%	-0.11%	6.71%	0.77%	-0.55%	1.52%	-1.03%	-7.32%	1.02%
EBITDA+	74.27M	64.84M	57.27M	95.74M	142.47M	107.12M	174.44M	96.85M	76.23M	90.09M
EBITDA Margin %	0.15%	0.09%	0.08%	0.12%	0.16%	0.12%	0.15%	0.07%	0.07%	0.08%
EBITDA Growth %	0.06%	-0.13%	-0.12%	0.67%	0.49%	-0.25%	0.63%	-0.44%	-0.21%	0.18%
D&A (Non-Cash Add-back)	25.64M	58.36M	51.51M	51.35M	64.12M	71.59M	84.93M	99.17M	95.56M	89.75M
EBIT	45.19M	21.41M	11.14M	44.39M	78.35M	35.53M	89.51M	-2.32M	-15.58M	337K
Net Interest Income+	-2.39M	0	0	0	-4.42M	-6.18M	-23.5M	-130K	14.76M	20.38M
Interest Income	0	0	0	0	4.42M	6.18M	23.5M	0	14.76M	24.9M
Interest Expense	2.39M	0	0	0	5.8M	2.1M	22.39M	130K	0	4.53M
Other Income/Expense	-2.39M	-8.43M	-6.63M	-8.78M	-4.42M	-6.18M	-23.5M	-130K	-779K	25.26M
Pretax Income+	46.24M	-1.95M	-879K	35.62M	73.93M	29.35M	66.01M	-2.45M	-20.11M	25.59M
Pretax Margin %	0.1%	-0%	-0%	0.05%	0.08%	0.03%	0.06%	-0%	-0.02%	0.02%
Income Tax+	15.48M	-2.55M	-21.48M	-2.11M	12.6M	-2.85M	-11.84M	-8.1M	263K	13.06M
Effective Tax Rate %	0.67%	-0.31%	-23.44%	1.06%	0.83%	1.1%	1.18%	-2.3%	1.01%	0.49%
Net Income+	30.76M	603K	20.61M	37.73M	61.34M	32.19M	77.85M	5.65M	-20.37M	12.53M
Net Margin %	0.06%	0%	0.03%	0.05%	0.07%	0.04%	0.07%	0%	-0.02%	0.01%
Net Income Growth %	0.01%	-0.98%	33.17%	0.83%	0.63%	-0.48%	1.42%	-0.93%	-4.61%	1.62%
Net Income (Continuing)	30.76M	603K	30.52M	37.73M	61.34M	32.19M	77.85M	5.65M	-20.37M	12.53M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.84	0.26	0.79	0.93	1.43	0.74	1.62	0.12	-0.45	0.27
EPS Growth %	0.01%	-0.69%	2.04%	0.18%	0.54%	-0.48%	1.19%	-0.93%	-4.75%	1.6%
EPS (Basic)	0.86	0.27	0.81	0.96	1.48	0.76	1.79	0.13	-0.45	0.27
Diluted Shares Outstanding	36.72M	36.86M	38.71M	40.56M	42.94M	43.74M	47.94M	45.89M	45.21M	46.26M
Basic Shares Outstanding	35.86M	36.16M	37.48M	39.24M	41.46M	42.58M	43.48M	44.4M	45.21M	46.05M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	264.13M	315.41M	367.12M	397.13M	483.24M	829.41M	780.7M	881.81M	927.57M	815.49M
Cash & Short-Term Investments	82.22M	54.49M	32.42M	67.19M	136.98M	496.17M	359.72M	341.85M	467.97M	381.68M
Cash Only	82.22M	54.49M	32.42M	67.19M	127.21M	485.93M	349.05M	330.36M	467.97M	369.2M
Short-Term Investments	0	0	0	0	9.77M	10.25M	10.66M	11.49M	0	12.47M
Accounts Receivable	107.96M	150.3M	198.81M	196.24M	218.36M	190.12M	240.89M	299.47M	263.89M	256.4M
Days Sales Outstanding	81.32	79.21	101.33	90.98	88.85	77.78	77.67	84.34	83.97	84.14
Inventory	46.59M	69.3M	96.14M	100.87M	108.01M	96.3M	119.92M	147.55M	110.1M	88.66M
Days Inventory Outstanding	71.87	66.77	89.04	88.72	85.68	73.39	75.81	76.18	62.09	50.47
Other Current Assets	7.77M	12.67M	4.5M	12.14M	1.06M	20.7M	31.01M	64.17M	51.36M	61.48M
Total Non-Current Assets+	314.62M	619.7M	613.18M	684.11M	757.57M	995.09M	1.36B	1.33B	1.3B	1.31B
Property, Plant & Equipment	32.31M	42.01M	42.59M	51.5M	110.38M	114.19M	119.69M	132.01M	133.59M	138.3M
Fixed Asset Turnover	15.00x	16.49x	16.81x	15.29x	8.13x	7.81x	9.46x	9.82x	8.59x	8.04x
Goodwill	147.91M	327.72M	337.75M	335.89M	336.54M	499.31M	738.9M	734.27M	735.81M	734.73M
Intangible Assets	89.67M	190.28M	168.11M	143.69M	209.94M	262.24M	374.61M	323.67M	277.83M	246.7M
Long-Term Investments	14.48M	20.59M	15.44M	17.08M	19.75M	22.16M	18.39M	32.92M	54.8M	52.74M
Other Non-Current Assets	27.89M	35.05M	39.84M	120.76M	66.83M	82.18M	94.32M	83.74M	64.37M	75.53M
Total Assets+	578.75M	935.1M	980.3M	1.08B	1.24B	1.82B	2.14B	2.21B	2.23B	2.12B
Asset Turnover	0.84x	0.74x	0.73x	0.73x	0.72x	0.49x	0.53x	0.59x	0.52x	0.52x
Asset Growth %	0.03%	0.62%	0.05%	0.1%	0.15%	0.47%	0.17%	0.03%	0.01%	-0.05%
Total Current Liabilities+	124.63M	180.91M	212.54M	204.58M	237M	276.42M	876.16M	428.45M	367.79M	595.68M
Accounts Payable	22.65M	27.07M	48.29M	38.04M	46.38M	40.31M	71.51M	63.39M	45.03M	51.78M
Days Payables Outstanding	34.93	26.08	44.73	33.46	36.79	30.72	45.21	32.73	25.39	29.48
Short-Term Debt	0	8.41M	15.21M	0	0	0	488.15M	0	0	174.32M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	30.13M	118.71M	114.47M	124.88M	44.16M	55.75M	71.13M	73.45M	126.02M	0
Current Ratio	2.12x	1.74x	1.73x	1.94x	2.04x	3.00x	0.89x	2.06x	2.52x	1.37x
Quick Ratio	1.75x	1.36x	1.28x	1.45x	1.58x	2.65x	0.75x	1.71x	2.22x	1.22x
Cash Conversion Cycle	118.26	119.89	145.64	146.24	137.74	120.45	108.28	127.8	120.67	105.13
Total Non-Current Liabilities+	51.73M	322.58M	250.57M	197.04M	158.56M	580.58M	119.65M	652.17M	670.13M	281.97M
Long-Term Debt	0	245.73M	194.92M	135.42M	50M	467.2M	0	566.57M	569.66M	166.4M
Capital Lease Obligations	0	0	0	0	50.67M	48.9M	39.91M	39.41M	33.91M	31.12M
Deferred Tax Liabilities	21.82M	51.59M	28.58M	41.48M	39.09M	39.63M	51.7M	2.1M	1.62M	1.11M
Other Non-Current Liabilities	11.93M	8.21M	9.83M	9.56M	11.72M	19.17M	7.84M	6.72M	6.32M	7.22M
Total Liabilities	176.36M	503.5M	463.11M	401.63M	395.56M	857M	995.81M	1.08B	1.04B	877.65M
Total Debt+	0	254.14M	210.13M	135.42M	110.73M	528.29M	541.01M	616.74M	614.09M	382.55M
Net Debt	-82.22M	199.65M	177.7M	68.22M	-16.48M	42.37M	191.96M	286.38M	146.12M	13.35M
Debt / Equity	-	0.59x	0.41x	0.20x	0.13x	0.55x	0.47x	0.55x	0.52x	0.31x
Debt / EBITDA	-	3.92x	3.67x	1.41x	0.78x	4.93x	3.10x	6.37x	8.06x	4.25x
Net Debt / EBITDA	-1.11x	3.08x	3.10x	0.71x	-0.12x	0.40x	1.10x	2.96x	1.92x	0.15x
Interest Coverage	20.37x	-	-	-	13.50x	16.94x	4.00x	-17.87x	-	0.07x
Total Equity+	402.39M	431.61M	517.2M	679.62M	845.25M	967.5M	1.15B	1.13B	1.19B	1.24B
Equity Growth %	0.03%	0.07%	0.2%	0.31%	0.24%	0.14%	0.19%	-0.01%	0.05%	0.05%
Book Value per Share	10.96	11.71	13.36	16.76	19.68	22.12	23.92	24.63	26.30	26.88
Total Shareholders' Equity	402.39M	431.61M	517.2M	679.62M	845.25M	967.5M	1.15B	1.13B	1.19B	1.24B
Common Stock	45K	46K	48K	50K	51K	53K	54K	55K	56K	57K
Retained Earnings	99.79M	100.4M	122.58M	197.45M	258.79M	290.72M	368.57M	390.73M	370.36M	382.89M
Treasury Stock	-185.07M	-185.07M	-185.07M	-185.07M	-185.07M	-238.11M	-238.11M	-290.32M	-290.32M	-290.32M
Accumulated OCI	-2.73M	-9.52M	-6.11M	-10.85M	-9.45M	-5.52M	-8.41M	-17.09M	-13.43M	-17.2M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	33.76M	47.94M	24.83M	103.97M	145.01M	185.87M	231.81M	77.78M	181.09M	187.72M
Operating CF Margin %	0.07%	0.07%	0.03%	0.13%	0.16%	0.21%	0.2%	0.06%	0.16%	0.17%
Operating CF Growth %	-0.48%	0.42%	-0.48%	3.19%	0.39%	0.28%	0.25%	-0.66%	1.33%	0.04%
Net Income	30.76M	603K	20.61M	37.73M	61.34M	32.19M	77.85M	5.65M	-20.37M	12.53M
Depreciation & Amortization	25.64M	58.36M	51.51M	51.35M	64.12M	71.59M	106.98M	99.17M	95.56M	89.75M
Stock-Based Compensation	14.92M	19.5M	21.86M	28.89M	34.05M	44.7M	53.16M	68.25M	0	39.32M
Deferred Taxes	-1.09M	-10.88M	-26.84M	-5.71M	-1.34M	-6.55M	0	-37.32M	-11.05M	-14.86M
Other Non-Cash Items	-2.67M	764K	2.11M	2.42M	2.65M	6.63M	50.42M	15.5M	73.28M	2.64M
Working Capital Changes	-33.8M	-20.41M	-44.41M	-10.72M	-15.81M	37.3M	-56.6M	-73.47M	43.67M	58.33M
Change in Receivables	-18.3M	8.05M	-39.07M	-6.19M	-23.52M	12.03M	-40.97M	-60.36M	38.74M	-5M
Change in Inventory	-10.4M	-3.36M	-26.84M	-6.76M	-8.12M	12.36M	-25.7M	-30.11M	38.02M	5.39M
Change in Payables	-2.84M	-4.96M	19.71M	-9.15M	7.89M	-6.3M	0	-7.75M	-17.52M	7.21M
Cash from Investing+	-45.6M	-341.32M	-34.99M	-54.37M	-61.66M	-279.87M	-412.5M	-58.67M	-55.02M	-52.79M
Capital Expenditures	-20.09M	-29.16M	-30.54M	-54.37M	-61.66M	-54.87M	-28.97M	-60.74M	-55.02M	-36.46M
CapEx % of Revenue	0.04%	0.04%	0.04%	0.07%	0.07%	0.06%	0.03%	0.05%	0.05%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-12.55M	-15.72M	-15.2M	1.68M	3.7M	-29.14M	-29.37M	15.35M	0	-5.93M
Cash from Financing+	-31.83M	265.71M	-9.88M	-13.6M	-23.48M	456.27M	47.36M	-20.95M	23.42M	-235.58M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	18.19M	11.2M	39.52M	23.84M	28.71M	8.38M	63.65M	31.26M	3.17M	-48.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	13.67M	18.77M	-5.71M	49.59M	83.34M	131M	202.84M	17.04M	139.62M	151.26M
FCF Margin %	0.03%	0.03%	-0.01%	0.06%	0.09%	0.15%	0.18%	0.01%	0.12%	0.14%
FCF Growth %	-0.68%	0.37%	-1.3%	9.69%	0.68%	0.57%	0.55%	-0.92%	7.19%	0.08%
FCF per Share	0.37	0.51	-0.15	1.22	1.94	2.99	4.23	0.37	3.09	3.27
FCF Conversion (FCF/Net Income)	1.10x	79.50x	1.21x	2.76x	2.36x	5.77x	2.98x	13.77x	-8.89x	14.98x
Interest Paid	76K	5.34M	6.55M	7.49M	3.58M	522K	1.92M	1.44M	0	1.62M
Taxes Paid	11.87M	11.09M	7.78M	3.49M	7.76M	10.34M	0	19M	0	11.28M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	7.76%	0.14%	4.34%	6.3%	8.04%	3.55%	7.36%	0.5%	-1.76%	1.03%
Return on Invested Capital (ROIC)	12.48%	1.02%	0.65%	4.62%	7.45%	2.9%	5.72%	-0.13%	-1.05%	0.02%
Gross Margin	51.17%	45.31%	44.97%	47.29%	48.71%	46.32%	49%	45.45%	43.58%	42.35%
Net Margin	6.35%	0.09%	2.88%	4.79%	6.84%	3.61%	6.88%	0.44%	-1.78%	1.13%
Debt / Equity	-	0.59x	0.41x	0.20x	0.13x	0.55x	0.47x	0.55x	0.52x	0.31x
Interest Coverage	20.37x	-	-	-	13.50x	16.94x	4.00x	-17.87x	-	0.07x
FCF Conversion	1.10x	79.50x	1.21x	2.76x	2.36x	5.77x	2.98x	13.77x	-8.89x	14.98x
Revenue Growth	9.9%	42.94%	3.4%	9.93%	13.94%	-0.54%	26.88%	14.48%	-11.48%	-3.04%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Connected Devices, Software Licenses, And Other	-	-	-	-	-	560.37M	739.07M	827.92M	623.58M	539.17M
Connected Devices, Software Licenses, And Other Growth	-	-	-	-	-	-	31.89%	12.02%	-24.68%	-13.54%
Advanced Services	-	-	-	-	-	-	-	-	212.72M	243.52M
Advanced Services Growth	-	-	-	-	-	-	-	-	-	14.48%
Technical Services	-	-	-	-	-	202.38M	206.99M	206.69M	225.83M	238.21M
Technical Services Growth	-	-	-	-	-	-	2.28%	-0.15%	9.26%	5.48%
Consumables	-	-	-	-	88.88M	75.66M	73.44M	75.31M	84.98M	91.34M
Consumables Growth	-	-	-	-	-	-14.87%	-2.94%	2.54%	12.84%	7.49%
Hardware And Software	-	-	-	-	553.04M	53.79M	112.52M	186.04M	-	-
Hardware And Software Growth	-	-	-	-	-	-90.27%	109.16%	65.34%	-	-
Product	-	-	-	569.6M	659.6M	-	-	-	-	-
Product Growth	-	-	-	-	15.80%	-	-	-	-	-
Product, Other	-	-	-	-	17.69M	-	-	-	-	-
Product, Other Growth	-	-	-	-	-	-	-	-	-	-
Service	-	-	-	217.71M	-	-	-	-	-	-
Service Growth	-	-	-	-	-	-	-	-	-	-
Automation and Analytics	390.32M	593.63M	590.39M	-	-	-	-	-	-	-
Automation and Analytics Growth	-	52.09%	-0.54%	-	-	-	-	-	-	-
Medication Adherence	94.24M	99M	125.77M	-	-	-	-	-	-	-
Medication Adherence Growth	-	5.05%	27.05%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	403.38M	591.57M	617.27M	685.88M	806.9M	797.6M	1.02B	1.17B	1.01B	1.01B
UNITED STATES Growth	-	46.65%	4.34%	11.12%	17.64%	-1.15%	27.98%	14.44%	-13.42%	0.10%
Non-US	81.18M	101.06M	98.9M	101.43M	90.13M	94.61M	111.23M	127.75M	135.73M	99.86M
Non-US Growth	-	24.48%	-2.14%	2.56%	-11.14%	4.97%	17.57%	14.85%	6.25%	-26.42%

Frequently Asked Questions

Valuation & Price

Omnicell, Inc. (OMCL) has a price-to-earnings (P/E) ratio of 187.9x. This suggests investors expect higher future growth.

Growth & Financials

Omnicell, Inc. (OMCL) reported $1.18B in revenue for fiscal year 2024. This represents a 380% increase from $245.5M in 2011.

Omnicell, Inc. (OMCL) saw revenue decline by 3.0% over the past year.

Yes, Omnicell, Inc. (OMCL) is profitable, generating $19.9M in net income for fiscal year 2024 (1.1% net margin).

Dividend & Returns

Omnicell, Inc. (OMCL) has a return on equity (ROE) of 1.0%. This is below average, suggesting room for improvement.

Omnicell, Inc. (OMCL) generated $111.5M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...